Skip to main content
Clinical Trials/NCT00714961
NCT00714961
Completed
Phase 3

A Randomized, Double-Blind, Placebo-Controlled Trial Comparing Clopidogrel Plus Acetylsalicylic Acid (ASA) Versus ASA Alone in Subjects With Acute ST Elevation Myocardial Infarction (STEMI) Treated With Fibrinolytic Therapy

Sanofi16 sites in 16 countries3,491 target enrollmentStarted: February 2003Last updated:

Overview

Phase
Phase 3
Status
Completed
Sponsor
Sanofi
Enrollment
3,491
Locations
16
Primary Endpoint
safety: TIMI major bleeding

Overview

Brief Summary

The purpose of this study is to determine if the combination of aspirin plus clopidogrel is more effective than aspirin alone in preventing another heart attack, chest pain, stroke or death in people who have already had a heart attack that was treated with fibrinolytic therapy.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Prevention
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Eligibility Criteria

Ages
18 Years to 75 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • STEMI within 12 hours of randomization
  • Planned treatment with a fibrinolytic agent and aspirin

Exclusion Criteria

  • Intention of performing coronary angiography within 48 hours of fibrinolysis
  • Treatment with clopidogrel or ticlopidine within 7 days prior to enrollment, or planned treatment with clopidogrel or ticlopidine.
  • Contraindication to fibrinolysis
  • Planned use of a glycoprotein IIb/IIIa inhibitor
  • Prior CABG
  • Evidence of cardiogenic shock or acute pulmonary edema requiring intubation or an intraaortic balloon pump
  • Known renal or hepatic insufficiency

Arms & Interventions

1

Experimental

Intervention: Clopidogrel (SR25990) (Drug)

2

Placebo Comparator

Intervention: Placebo (Drug)

Outcomes

Primary Outcomes

safety: TIMI major bleeding

efficacy: composite of an included infarct-related artery on the pre-discharge angiogram, or death or recurrent MI by the time of the start of coronary angiography

Secondary Outcomes

  • Angiographic, clinical and electrocardiographic outcomes

Investigators

Sponsor
Sanofi
Sponsor Class
Industry

Study Sites (16)

Loading locations...

Similar Trials